That shift matters because the first wave of wearables was largely built around activity. Steps, calories, heart rate, sleep and workout tracking helped consumers understand their bodies in a more continuous way. But most of this data was descriptive. It told users what happened, not always what it meant.

The next wave is more ambitious. It is trying to move from fitness data to biological signals that could help users understand recovery, fatigue, stress, sleep quality, glucose levels, oxygenation, cardiovascular strain and cognitive performance. This is where Temple becomes an interesting signal. The company is building a wearable focused on cerebral blood flow, a much more complex metric than what most consumer wearables currently track. Temple raised US$54 million in seed funding at a post money valuation of around US$190 million, with investors reportedly including Steadview Capital and Peak XV Partners.

The point is not that Temple has already solved the problem. It has not. The point is that investor interest in a product like Temple shows where the category is moving. Wearables are no longer only competing on screen size, battery life, step counts or smartwatch features. The new competition is around who can generate more useful health signals, interpret them accurately, and turn them into trusted decisions.

This is also why the category is getting harder. Consumer fitness devices can succeed with good design, habit formation and basic accuracy. Performance health devices face a higher bar. If a device claims to measure a serious biological signal, the question is not just whether the product is beautiful or whether the founder is credible. The question is whether the measurement is repeatable, clinically meaningful and useful in real life.

That is the core tension around Temple. In January 2026, medical experts publicly questioned the scientific basis of the device, citing lack of clinical proof and warning that health devices need rigorous validation before users treat them as reliable medical tools. Goyal also clarified at the time that Temple was still unvalidated and had not released official benchmarking data.

Since then, Temple appears to have moved from curiosity to early access. In May 2026, Goyal said the first 100 Temple devices were ready to ship, with applications open for a limited group of founding users including athletes, scientists, founders, doctors and creators. That is still not a mass market launch. It is closer to a controlled early user rollout, which makes sense for a product that needs feedback, validation and careful positioning.

This is where the broader industry lesson sits. The future of wearables will not be won by the company that collects the most data. It will be won by the company that makes health data useful, trusted and actionable.

For users, that means fewer vanity metrics and more meaningful interpretation. For athletes, it could mean better recovery and performance management. For doctors and researchers, it could mean richer longitudinal data, if the devices are validated properly. For insurers and healthcare systems, it could eventually mean earlier risk detection and more preventive care models. But each of these use cases depends on trust.

That trust will have three layers.

First, scientific trust. The device has to measure what it claims to measure.

Second, clinical trust. The metric has to matter in a real health or performance context.

Third, behavioural trust. The user has to know what to do with the insight.

Many wearables fail at the third layer. They generate data, but not decisions. A user sees a score, graph or alert, but does not know whether to rest, train, see a doctor, sleep more, change diet or ignore the signal. As wearables move deeper into health, this gap becomes more important.

That is why Temple is strategically interesting even before it is commercially proven. It sits at the edge of a broader shift from consumer electronics to consumer health infrastructure. The product may work, fail, pivot or remain niche. But the direction of travel is clear: the wearable market is moving toward deeper signals, higher validation requirements and more serious health claims.

The winners in this next phase will not simply be hardware companies. They will need hardware, sensor science, clinical validation, data interpretation, consumer trust and probably some form of healthcare ecosystem integration. That is a much harder business than selling a smartwatch.

Temple should therefore be read less as a finished product and more as a signal. It reflects where founders and investors believe the market is going: from tracking activity to understanding performance, from passive metrics to actionable health signals, and from lifestyle devices to scientifically credible health tools.

‍